Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
JAZZ [NASD]
Jazz Pharmaceuticals plc
Index- P/E40.34 EPS (ttm)3.51 Insider Own4.20% Shs Outstand58.07M Perf Week4.03%
Market Cap8.22B Forward P/E13.94 EPS next Y10.16 Insider Trans-6.12% Shs Float55.25M Perf Month3.56%
Income216.30M PEG1.98 EPS next Q1.91 Inst Own89.00% Short Float2.73% Perf Quarter-11.00%
Sales872.40M P/S9.42 EPS this Y-19.10% Inst Trans1.30% Short Ratio1.16 Perf Half Y56.42%
Book/sh22.38 P/B6.33 EPS next Y23.77% ROA10.10% Target Price181.64 Perf Year154.64%
Cash/sh10.96 P/C12.92 EPS next 5Y20.40% ROE17.70% 52W Range53.29 - 176.60 Perf YTD11.87%
Dividend- P/FCF30.19 EPS past 5Y20.00% ROI13.30% 52W High-19.83% Beta1.05
Dividend %- Quick Ratio4.10 Sales past 5Y66.80% Gross Margin88.30% 52W Low165.68% ATR7.39
Employees810 Current Ratio4.20 Sales Q/Q28.40% Oper. Margin39.90% RSI (14)49.85 Volatility4.76% 5.65%
OptionableYes Debt/Eq0.42 EPS Q/Q-66.30% Profit Margin24.80% Rel Volume0.84 Prev Close143.91
ShortableYes LT Debt/Eq0.42 EarningsMay 05 Payout0.00% Avg Volume1.30M Price141.58
Recom1.70 SMA204.98% SMA50-4.44% SMA20024.39% Volume1,086,522 Change-1.62%
17-Apr-14Initiated Canaccord Genuity Buy $163
07-Mar-14Resumed Barclays Overweight $200
26-Feb-14Reiterated Stifel Buy $145 → $195
14-Jan-14Reiterated UBS Buy $130 → $164
14-Jan-14Downgrade R. F. Lafferty Buy → Neutral $140
06-Dec-13Reiterated UBS Buy $110 → $130
25-Nov-13Reiterated FBR Capital Outperform $105 → $198
25-Nov-13Reiterated Barclays Overweight $112 → $130
13-Nov-13Reiterated R. F. Lafferty Buy $102 → $118
30-Oct-13Initiated FBR Capital Outperform $105
13-Sep-13Reiterated UBS Buy $87 → $98
22-Aug-13Initiated R. F. Lafferty Buy $102
07-Aug-13Reiterated UBS Buy $80 → $87
07-Aug-13Reiterated Cantor Fitzgerald Buy $86 → $97
07-Aug-13Reiterated Barclays Overweight $70 → $85
31-May-13Initiated Stifel Buy $80
11-Mar-13Initiated Cantor Fitzgerald Buy $86
27-Feb-13Reiterated UBS Buy $64 → $67
23-May-12Initiated Oppenheimer Outperform $66
09-May-12Reiterated Mizuho Buy $75 → $80
24-Apr-14 04:05PM  Jazz Pharmaceuticals to Report 2014 First Quarter Financial Results on May 8, 2014 PR Newswire
23-Apr-14 07:03PM  3 Stocks to Get on Your Watchlist at Motley Fool
22-Apr-14 06:04PM  Market shift could drive further advance: Cramer at CNBC +5.07%
02:06PM  This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value at Motley Fool
10:15AM  Insider Trading Alert - BIIB, JAZZ And KWK Traded By Insiders at TheStreet
09:46AM  Jazz Pharmaceuticals (JAZZ) On Momo Momentum Watch Today at TheStreet
07:51AM  Allergan could fend off Valeant with acquisition, says Jefferies theflyonthewall.com
06:08AM  Equities With Best Wealth-Building Odds, Big Rates Of Gain Now In Next 6 Months at Seeking Alpha
17-Apr-14 06:32PM  How Are Orphan Drugmakers Faring in the Great Biotech Downturn? at Motley Fool
07:59AM  Coverage initiated on Jazz Pharma by Canaccord Genuity Briefing.com
14-Apr-14 09:01PM  Positive News And Stocks At Bargain Prices at Seeking Alpha
11-Apr-14 10:15AM  Insider Trading Alert - JAZZ, GDOT And MDSO Traded By Insiders at TheStreet
09-Apr-14 12:17PM  Jazz Pharma: Risk 7% Downside, 34% Upside To Fair Value at Seeking Alpha +5.24%
12:17PM  Jazz Pharma: Risk 1% Downside, 34% Upside To Fair Value at Seeking Alpha
08-Apr-14 06:32PM  Ethical Drug Stocks Are Struggling at Investor's Business Daily
07-Apr-14 11:44AM  Commit To Purchase Jazz Pharmaceuticals At $105, Earn 11.2% Annualized Using Options at TheStreet
09:41AM  $5.6 Billion Questcor Deal Means High Drug Prices For Everybody at Forbes
04-Apr-14 02:11PM  3 Reasons an Ariad Pharmaceuticals Buyout Is Unlikely at Motley Fool -6.18%
03-Apr-14 08:21AM  10 Best-Buy Wealth-Building Bets, Odds-On Payoffs, In 6 Months Or Less at Seeking Alpha
02-Apr-14 05:17PM  Is an Ariad Pharmaceuticals, Inc. Acquisition Realistic? at Motley Fool
01-Apr-14 03:38PM  Markets Are Rigged Zacks
31-Mar-14 03:04PM  From Marijuana to Snake Venom: 9 Drugs Derived from Unlikely Sources at Motley Fool
08:00AM  Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease PR Newswire
28-Mar-14 09:25AM  On The Fly: Pre-market Movers at theflyonthewall.com
08:59AM  Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp at Motley Fool
21-Mar-14 06:26PM  Biotechs, Medicals Get Hurt Amid Price-Inquiry News at Investor's Business Daily
09:59AM  Jazz Leads Best 25 Market-Maker Equities Higher, Sensing Renewed Price Strength at Seeking Alpha
20-Mar-14 12:03PM  Jeff Cooper: Will Investors Lose Faith in the Rally and the Fed? at Minyanville
19-Mar-14 10:45AM  Horizon Pharma To Buy Vidara, Join Exodus To Ireland at Investor's Business Daily
10:10AM  Are Biotech Stocks Located in Ireland Top Buyout Candidates? at 24/7 Wall St.
10:10AM  Are Biotech Stocks Located in Ireland Top Buyout Candidates?
13-Mar-14 10:34AM  Stocks Open To Modest Gains; Amazon Jumps On Prime Price Hike at Investor's Business Daily -5.19%
10:34AM  Stocks Open To Modest Gains; Amazon Jumps On Prime Price Hike
09:06AM  Jazz Pharmaceuticals 3.2M share Block Trade priced at $154.00 theflyonthewall.com
09:06AM  Jazz Pharmaceuticals 3.2M share Block Trade priced at $154.00
11-Mar-14 05:23PM  Looking For Watch List Ideas? Find Them In Sector Leaders Optionetics
05:23PM  Looking For Watch List Ideas? Find Them In Sector Leaders Investor's Business Daily
11:19AM  Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI Gurufocus
11:19AM  Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI
10-Mar-14 12:47PM  Celgene, Jazz, And Risk-Reward In The Biotech Industry at Seeking Alpha
07-Mar-14 05:49PM  Highflying Drug, Biotech Stocks Take Rare Drubbing at Investor's Business Daily
05:49PM  Highflying Drug, Biotech Stocks Take Rare Drubbing
04:28PM  Nasdaq Lags As Stock Market Closes Lower at Investor's Business Daily
04:28PM  Nasdaq Lags As Stock Market Closes Lower
10:31AM  Stocks Open Higher, Turn Mixed After Employment Report at Investor's Business Daily
10:31AM  Stocks Open Higher, Turn Mixed After Employment Report
10:31AM  Stocks Open Higher, Turn Mixed After Employement Report at Investor's Business Daily
06-Mar-14 05:29PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events EDGAR Online
05:00PM  Stock Market Closes Mixed; Ambarella Tops Expectations at Investor's Business Daily
05:00PM  Stock Market Closes Mixed; Ambarella Tops Expectations
04:13PM  Stock Market Closes Mixed; Medical Leaders Drop at Investor's Business Daily
04:13PM  Stock Market Closes Mixed; Medical Leaders Drop
02:00PM  Insider Trading Alert - IP, CYBX And JAZZ Traded By Insiders at TheStreet
04-Mar-14 02:39PM  New Government in Italy: How Will It Affect These Italian ADRs? at Motley Fool
01-Mar-14 01:04PM  JAZZ PHARMACEUTICALS PLC Financials EDGAR Online Financials
28-Feb-14 04:25PM  Leaders Take Hits; Nasdaq Reverses After Early Strength at Investor's Business Daily -8.80%
01:28PM  Major Indexes Hold Near New Milestones; MasTec Surges at Investor's Business Daily
07:08AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events, Financial Statemen EDGAR Online
26-Feb-14 06:37PM  Drugmakers Like Jazz, Shire Key To Europe's Recovery at Investor's Business Daily -7.38%
06:00PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
12:01PM  Nasdaq Hits New Multiyear High; SolarCity Heats Up at Investor's Business Daily
11:00AM  Jazz Pharma's Q4 Results, Guidance Get Mixed Reaction at Investor's Business Daily
10:38AM  Stocks And Volume Start Mixed; January New Home Sales Positive at Investor's Business Daily
09:50AM  Jazz Pharma Misses on Earnings, Outlook Encourages Zacks
09:09AM  Stock Futures In Positive Mood; Jazz, First Solar Get Whacked at Investor's Business Daily
07:33AM  Jazz Pharmaceuticals price target raised to $207 from $171 at Brean Capital theflyonthewall.com
25-Feb-14 11:06PM  Jazz Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
06:18PM  Jazz Sings Blues On Q4 Sales, Earnings Investor's Business Daily
06:04PM  Michael Kors: Why This Fund Manager Likes The Stock at Investor's Business Daily
05:39PM  Jazz Pharmaceuticals Profit Jumps 13% on Strong Xyrem Sales at Motley Fool
04:56PM  Stocks End Lower; First Solar Plunges After Hours at Investor's Business Daily
04:30PM  Jazz Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN
04:25PM  Jazz Pharmaceuticals, Inc. Discusses Q4 2013 Results (Webcast) at Seeking Alpha
04:22PM  Jazz Pharmaceuticals CFO Kathryn Falberg to step down theflyonthewall.com
04:13PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr EDGAR Online
04:07PM  Jazz Pharmaceuticals Announces Management Change PR Newswire
04:05PM  Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2013 Financial Results PR Newswire
01:54PM  The case for the bears weakens at MarketWatch
11:01AM  Biotech Showdown: Questcor Pharmaceuticals Inc. vs. Jazz Pharmaceuticals plc at Motley Fool
07:07AM  Q4 2013 Jazz Pharmaceuticals Earnings Release - After Market Close CCBN
03:47AM  Mr. Market Loves Jazz Pharmaceuticals, Time To Sell at Seeking Alpha
24-Feb-14 12:48PM  Jazz Pharma To Guide 2014 With New Drugs On Board at Investor's Business Daily
22-Feb-14 08:02AM  Valeant, Jazz Among IBD 50 Stocks Earnings This Week at Investor's Business Daily
21-Feb-14 08:00AM  Jazz Pharmaceuticals plc Completes Tender Offer For Gentium S.p.A. Shares PR Newswire
20-Feb-14 04:40PM  Jazz Pharmaceuticals Moves Up In Market Cap Rank, Passing Waters at TheStreet
18-Feb-14 11:30AM  Insider Trading Alert - MJN, JAZZ And CLB Traded By Insiders at TheStreet +7.38%
14-Feb-14 05:17PM  A Lean, Wary Post-Bailout Ireland Begets Rising Stocks at Investor's Business Daily
13-Feb-14 01:00AM  IPO Preview: Concert Pharmaceuticals at Seeking Alpha
11-Feb-14 04:07PM  Jazz Pharmaceuticals to Report 2013 Fourth Quarter and Full Year Financial Results on February 25, 2014 PR Newswire
04:05PM  Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz (clozapine, USP) Oral Suspension PR Newswire
12:11PM  Top Ranked Healthcare ETF in Focus: XPH Zacks
12:10PM  Jazz Pharma Invests in Ireland Zacks
11:29AM  Jazz Pharma Still Making Investors Sing at TheStreet
10-Feb-14 08:05AM  Jazz Pharmaceuticals Breaks Ground On New Manufacturing And Development Facility In Ireland PR Newswire
09-Feb-14 02:11PM  4 New Issues IPO Investors Need to Know About for This Week at Motley Fool
07-Feb-14 04:22PM  Stocks End Week On High Note; Priceline Gaps Above 50-Day at Investor's Business Daily +6.48%
01:22PM  Stocks Extend Gains, Nasdaq Retakes 50-Day Line at Investor's Business Daily
06-Feb-14 05:21PM  Jazz, Valeant Pace Highly Rated Ethical Drugs Group at Investor's Business Daily
05-Feb-14 01:58AM  2014: A Billion Dollar Year For Jazz Pharmaceuticals at Seeking Alpha
02-Feb-14 02:25PM  Is Alexion Pharmaceuticals Deserving of Its 20% Post-Earnings Pop? at Motley Fool
Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hooper Suzanne SawochkaEVP and General CounselApr 17Option Exercise46.8366731,23657,802Apr 21 07:59 PM
Hooper Suzanne SawochkaEVP and General CounselApr 17Sale140.0066793,38057,135Apr 21 07:59 PM
Winningham Rick EDirectorApr 17Sale140.0027,5003,850,00013,587Apr 21 07:55 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Option Exercise53.883,000161,64651,103Apr 16 07:41 PM
Tobias Jeffrey KEVP, Research & Dev and CMOApr 14Sale128.543,000385,62048,103Apr 16 07:41 PM
Keegan FintanEVP, Technical OperationsApr 08Sale130.0075097,50038,522Apr 10 08:37 PM
COZADD BRUCE CChairman and CEOApr 08Sale123.185,000615,900611,810Apr 10 08:34 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Option Exercise53.883,000161,63451,103Mar 12 06:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOMar 10Sale152.993,000458,97048,103Mar 12 06:06 PM
WILSON KAREN JSVP, Finance & PAOMar 07Option Exercise59.133,000177,39027,300Mar 11 08:26 PM
WILSON KAREN JSVP, Finance & PAOMar 07Sale155.043,888602,79623,412Mar 11 08:26 PM
Keegan FintanEVP, Technical OperationsMar 06Sale157.891,634257,99239,272Mar 06 07:01 PM
Mulligan SeamusDirectorMar 04Sale156.25550,00085,937,5001,455,555Mar 05 05:19 PM
Keegan FintanEVP, Technical OperationsMar 04Sale161.003,006483,96640,906Mar 06 07:01 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Option Exercise46.8311,250526,83832,582Mar 03 08:14 PM
WILSON KAREN JSVP, Finance & PAOFeb 27Sale166.7711,2501,876,15021,332Mar 03 08:14 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 27Sale165.463,000496,38041,777Mar 03 08:05 PM
COZADD BRUCE CChairman and CEOFeb 27Sale158.3625,0003,959,000600,754Mar 03 07:21 PM
Cox Russell J.EVP & Chief Commercial OfficerFeb 27Sale164.594,000658,36050,024Mar 03 07:10 PM
FALBERG KATHRYN EEVP and CFOFeb 26Option Exercise7.3510,20474,999134,925Feb 27 08:08 PM
FALBERG KATHRYN EEVP and CFOFeb 12Sale157.002,000314,000124,721Feb 14 07:09 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Option Exercise46.832,560119,88547,337Feb 12 07:18 PM
Tobias Jeffrey KEVP, Research & Dev and CMOFeb 10Sale152.832,560391,24544,777Feb 12 07:18 PM
FALBERG KATHRYN EEVP and CFOJan 08Sale131.822,000263,640126,721Jan 10 08:26 PM
FALBERG KATHRYN EEVP and CFODec 11Sale120.503,000361,500128,721Dec 13 07:49 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Option Exercise46.831,32562,05046,102Dec 11 07:01 PM
Tobias Jeffrey KEVP, Research & Dev and CMODec 09Sale117.801,325156,08544,777Dec 11 07:01 PM
FALBERG KATHRYN EEVP and CFONov 13Sale100.883,000302,640131,372Nov 15 06:16 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 11Option Exercise46.832,373111,12846,778Nov 13 06:57 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 11Sale98.502,373233,74144,405Nov 13 06:57 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 14Option Exercise46.835,000234,15049,405Oct 16 06:54 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 14Sale82.625,000413,11844,405Oct 16 06:54 PM
FALBERG KATHRYN EEVP and CFOOct 09Sale83.103,000249,300134,372Oct 11 06:55 PM
COZADD BRUCE CChairman and CEOOct 08Sale88.584,000354,320625,647Oct 10 06:28 PM
FALBERG KATHRYN EEVP and CFOSep 11Sale87.523,000262,560137,372Sep 13 05:56 PM
COZADD BRUCE CChairman and CEOSep 10Sale87.595,000437,950629,647Sep 10 06:11 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 09Option Exercise46.835,000234,15049,405Sep 10 06:03 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 09Sale87.115,000435,55044,405Sep 10 06:03 PM
Cox Russell J.EVP & Chief Commercial OfficerSep 04Sale88.161,00088,16052,736Sep 04 05:48 PM
WILSON KAREN JSVP, Finance & PAOAug 30Sale87.622,000175,24021,075Sep 04 05:28 PM
FALBERG KATHRYN EEVP and CFOAug 14Sale81.023,000243,060140,372Aug 14 07:17 PM
Sohn Catherine A.DirectorAug 14Sale81.0264051,8535,610Aug 14 07:13 PM
Keegan FintanEVP, Technical OperationsAug 13Sale81.447,454607,02236,412Aug 14 07:54 PM
Winningham Rick EDirectorAug 13Sale81.861,07087,59041,087Aug 14 07:15 PM
MOMTAZEE JAMES CDirectorAug 13Sale81.861,07087,59017,315Aug 14 07:12 PM
ENRIGHT PATRICK GDirectorAug 13Sale81.861,07087,5903,430Aug 14 07:10 PM
BERNS PAUL LDirectorAug 13Sale81.861,07087,5903,430Aug 14 07:08 PM
COZADD BRUCE CChairman and CEOAug 13Sale81.865,000409,300634,647Aug 13 09:00 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 12Option Exercise46.837,500351,22551,905Aug 13 09:03 PM
Keegan FintanEVP, Technical OperationsAug 12Sale80.831,21297,96643,866Aug 14 07:54 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 12Sale80.777,500605,77544,405Aug 13 09:03 PM
O'Keefe Kenneth WDirectorAug 08Sale81.32261,21221,241,7600Aug 09 05:02 PM
Cox Russell J.EVP & Chief Commercial OfficerAug 01Sale76.222,000152,44057,046Aug 02 08:30 PM
FALBERG KATHRYN EEVP and CFOJul 10Sale72.403,000217,200146,836Jul 12 05:53 PM
COZADD BRUCE CChairman and CEOJul 09Sale73.305,000366,500652,691Jul 10 08:45 PM
COZADD BRUCE CChairman and CEOJun 11Sale68.335,000341,650657,691Jun 11 08:23 PM
COZADD BRUCE CChairman and CEOJun 03Option Exercise11.481,45216,669662,691Jun 04 06:45 PM
COZADD BRUCE CChairman and CEOMay 21Sale60.001,00060,000660,643May 23 06:44 PM
Cox Russell J.EVP & Chief Commercial OfficerMay 20Sale58.541,00058,54058,769May 22 07:51 PM
COZADD BRUCE CChairman and CEOMay 14Sale58.524,000234,080661,643May 15 07:45 PM
COZADD BRUCE CChairman and CEOMay 03Sale60.001,00060,000665,643May 06 05:40 PM